Medicine
Stimate 1.5 mg/mL nasal spray
Stimate 1.5 mg/mL nasal spray is a prescription medicine containing Desmopressin for nasal use, marketed by Ferring Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at Controlled Room Temperature 20ºC to 25ºC (68ºF to 77ºF). Store bottle…
Key facts
- Active ingredient (INN)
- Desmopressin
- Brand
- Stimate
- Strength
- 1.5 mg/mL
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 2.5 mL
- Marketing authorisation holder
- Ferring Pharmaceuticals
- Manufacturer
- Ferring Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at Controlled Room Temperature 20ºC to 25ºC (68ºF to 77ºF). Store bottle in upright position.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01BA02 Desmopressin
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 June 2025
- Identifiers
- RxCUI 1797859, 1797861DailyMed set ID f5ada39c-20ed-4500-9dce-1e4ab642a358NDC 55566-3000Application NDA020355
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2.5 mL in 1 bottle, spray | 55566-3000-0 | Ferring Pharmaceuticals | 25 June 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 21 February 1978 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Desmopressin
Clinical summary
Desmopressin is a factor VIII activator indicated for the treatment of nephrogenic diabetes insipidus, among other approved uses. It is available as injection, tablets and nasal solution for intravenous, subcutaneous and oral use. MedsAcross supplies Desmopressin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DesmopressinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Desmopressin Acetate prescribing information (Nordic Pharma) · U.S. National Library of Medicine, DailyMed
Need Stimate 1.5 mg/mL nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.